Order Article Reprints

Poder A, Oberije J, Meyer J, Heymer P, Molrine D, Versage E, Isakov L, Zhang Q, Hohenboken M. Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age. Vaccines. 2023; 11(10):1528. https://doi.org/10.3390/vaccines11101528

Poder, Airi, Janine Oberije, Jay Meyer, Peter Heymer, Deborah Molrine, Eve Versage, Leah Isakov, Qiuhong Zhang, and Matthew Hohenboken. 2023. "Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age" Vaccines 11, no. 10: 1528. https://doi.org/10.3390/vaccines11101528

Poder, A., Oberije, J., Meyer, J., Heymer, P., Molrine, D., Versage, E., Isakov, L., Zhang, Q., & Hohenboken, M. (2023). Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age. Vaccines, 11(10), 1528. https://doi.org/10.3390/vaccines11101528